CN113769108B - 半胱氨酸工程化抗体的结合物 - Google Patents

半胱氨酸工程化抗体的结合物 Download PDF

Info

Publication number
CN113769108B
CN113769108B CN202111168673.4A CN202111168673A CN113769108B CN 113769108 B CN113769108 B CN 113769108B CN 202111168673 A CN202111168673 A CN 202111168673A CN 113769108 B CN113769108 B CN 113769108B
Authority
CN
China
Prior art keywords
ala
group
conjugate
val
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111168673.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113769108A (zh
Inventor
N·C·尤德
白晨
M·L·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Priority to CN202111168673.4A priority Critical patent/CN113769108B/zh
Publication of CN113769108A publication Critical patent/CN113769108A/zh
Application granted granted Critical
Publication of CN113769108B publication Critical patent/CN113769108B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202111168673.4A 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物 Active CN113769108B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111168673.4A CN113769108B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186254P 2015-06-29 2015-06-29
US62/186,254 2015-06-29
US201662338245P 2016-05-18 2016-05-18
US62/338,245 2016-05-18
CN202111168673.4A CN113769108B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物
PCT/US2016/039796 WO2017004025A1 (en) 2015-06-29 2016-06-28 Conjugates of cysteine engineered antibodies
CN201680038492.0A CN107708810B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680038492.0A Division CN107708810B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物

Publications (2)

Publication Number Publication Date
CN113769108A CN113769108A (zh) 2021-12-10
CN113769108B true CN113769108B (zh) 2024-11-08

Family

ID=56409216

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680038492.0A Active CN107708810B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物
CN202111168673.4A Active CN113769108B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680038492.0A Active CN107708810B (zh) 2015-06-29 2016-06-28 半胱氨酸工程化抗体的结合物

Country Status (24)

Country Link
US (3) US10898579B2 (enExample)
EP (2) EP3769787A1 (enExample)
JP (4) JP6843080B2 (enExample)
KR (1) KR102793098B1 (enExample)
CN (2) CN107708810B (enExample)
AR (1) AR106013A1 (enExample)
AU (2) AU2016285929B2 (enExample)
CA (1) CA2988806C (enExample)
CY (1) CY1123606T1 (enExample)
DK (1) DK3313845T3 (enExample)
ES (1) ES2832527T3 (enExample)
HR (1) HRP20201790T1 (enExample)
HU (1) HUE052616T2 (enExample)
LT (1) LT3313845T (enExample)
MA (1) MA42250B1 (enExample)
MD (1) MD3313845T2 (enExample)
PL (1) PL3313845T3 (enExample)
PT (1) PT3313845T (enExample)
RS (1) RS61050B1 (enExample)
RU (1) RU2733740C2 (enExample)
SI (1) SI3313845T1 (enExample)
SM (1) SMT202000614T1 (enExample)
TW (2) TWI880021B (enExample)
WO (1) WO2017004025A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017027254A2 (pt) 2015-06-29 2019-05-14 Immunogen, Inc. anticorpos anti-cd123 e conjugados e derivados dos mesmos
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
TWI845890B (zh) 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
DK3558391T3 (da) 2016-12-23 2022-05-09 Immunogen Inc Immunkonjugater med adam9 som mål og fremgangsmåder til anvendelse deraf
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
TWI826393B (zh) 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
IL301638B2 (en) 2017-09-29 2024-09-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
MA54088A (fr) 2018-10-30 2022-03-16 Immunogen Inc Procédés de traitement faisant appel à des immunoconjugués anti-cd123
SG11202104423XA (en) * 2018-11-12 2021-05-28 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
CN112996792B (zh) * 2018-11-12 2024-04-26 伊缪诺金公司 制备细胞毒性苯并二氮杂卓衍生物的方法
WO2020100954A1 (ja) 2018-11-14 2020-05-22 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
WO2020191306A1 (en) * 2019-03-21 2020-09-24 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
WO2020196475A1 (ja) 2019-03-25 2020-10-01 第一三共株式会社 抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
JP7627655B2 (ja) 2019-03-25 2025-02-06 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
CA3139180A1 (en) 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CN113853217A (zh) 2019-04-29 2021-12-28 伊缪诺金公司 包含抗cd123免疫缀合物的治疗组合
KR20230061360A (ko) 2020-09-02 2023-05-08 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
CA3204628A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
TW202346322A (zh) 2022-03-02 2023-12-01 日商第一三共股份有限公司 含Ｆｃ分子之製造方法
US20250345449A1 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm
WO2025235924A2 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014339A1 (en) * 1994-11-05 1996-05-17 The Wellcome Foundation Limited Antibodies
CN103687623A (zh) * 2011-02-15 2014-03-26 伊缪诺金公司 细胞毒性苯并二氮杂*衍生物
CN110392685A (zh) * 2016-11-23 2019-10-29 伊缪诺金公司 苯并二氮卓衍生物的选择性磺化

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
WO2004043344A2 (en) 2002-11-07 2004-05-27 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
CN100381177C (zh) * 2003-01-27 2008-04-16 恩多塞特公司 维生素受体结合递药缀合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
CN102076717B (zh) 2008-04-30 2016-02-03 伊缪诺金公司 交联剂和它们的用途
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
US8426402B2 (en) * 2009-02-05 2013-04-23 Immunogen, Inc. Benzodiazepine derivatives
US8431416B2 (en) * 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011092838A1 (ja) 2010-01-29 2011-08-04 株式会社フォーサイド・ドット・コム コンテンツ共有システム、およびコンテンツ共有方法
SG10201501342UA (en) * 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
WO2013177481A1 (en) * 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
WO2014134457A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
PT3129406T (pt) * 2014-04-11 2019-04-24 Medimmune Llc Compostos conjugados que compreendem anticorpos com manipulação de cisteínas
JP2017528418A (ja) * 2014-06-20 2017-09-28 バイオアライアンス コマンディテール フェンノートシャップ 抗葉酸受容体アルファ（ｆｒａ）抗体−薬物コンジュゲート及びその使用方法
SG11201610624WA (en) * 2014-06-20 2017-01-27 Bioalliance Cv Anti-cd22 antibody-drug conjugates and methods of using thereof
CN106659783A (zh) * 2014-06-20 2017-05-10 艾比吉诺米克斯国际股份有限公司 Her2抗体‑药物缀合物
JP2017526682A (ja) 2014-09-02 2017-09-14 イミュノジェン， インコーポレイテッド 抗体薬物複合体組成物の製剤化方法
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
BR112017027254A2 (pt) 2015-06-29 2019-05-14 Immunogen, Inc. anticorpos anti-cd123 e conjugados e derivados dos mesmos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014339A1 (en) * 1994-11-05 1996-05-17 The Wellcome Foundation Limited Antibodies
CN103687623A (zh) * 2011-02-15 2014-03-26 伊缪诺金公司 细胞毒性苯并二氮杂*衍生物
CN110392685A (zh) * 2016-11-23 2019-10-29 伊缪诺金公司 苯并二氮卓衍生物的选择性磺化

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Julie B。Stimmel et al..Site-specific conjugation on serine cysteine variant monoclonal antibodies.《The journal of biological chemistry 》.2000,第275卷(第39期),30445. *
Pacholarz et al.Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry..《 EuPA open proteomics》.2016,第11卷23-27. *
Site-specific conjugation on serine cysteine variant monoclonal antibodies;Julie B。Stimmel et al.;《The journal of biological chemistry 》;第275卷(第39期);30445 *

Also Published As

Publication number Publication date
CA2988806A1 (en) 2017-01-05
JP6843080B2 (ja) 2021-03-17
JP2021088581A (ja) 2021-06-10
LT3313845T (lt) 2020-12-10
RU2733740C2 (ru) 2020-10-06
JP2022163185A (ja) 2022-10-25
KR20180021176A (ko) 2018-02-28
PL3313845T3 (pl) 2021-01-11
TW202146057A (zh) 2021-12-16
CA2988806C (en) 2024-09-10
TW201705983A (zh) 2017-02-16
DK3313845T3 (da) 2020-11-16
HK1254782A1 (en) 2019-07-26
MA42250B1 (fr) 2020-11-30
TWI740833B (zh) 2021-10-01
HUE052616T2 (hu) 2021-05-28
KR102793098B1 (ko) 2025-04-09
AU2016285929A1 (en) 2018-01-04
RU2017144859A (ru) 2019-07-30
AU2016285929B2 (en) 2022-01-06
RS61050B1 (sr) 2020-12-31
RU2017144859A3 (enExample) 2019-12-02
ES2832527T3 (es) 2021-06-10
JP7441281B2 (ja) 2024-02-29
EP3313845A1 (en) 2018-05-02
CN107708810A (zh) 2018-02-16
US20210085800A1 (en) 2021-03-25
CY1123606T1 (el) 2022-03-24
JP2018528162A (ja) 2018-09-27
EP3769787A1 (en) 2021-01-27
AU2022202208B2 (en) 2024-08-08
US20250011340A1 (en) 2025-01-09
US20170014522A1 (en) 2017-01-19
SMT202000614T1 (it) 2021-01-05
EP3313845B1 (en) 2020-08-12
US10898579B2 (en) 2021-01-26
PT3313845T (pt) 2020-11-19
MA42250A (fr) 2018-05-02
TWI880021B (zh) 2025-04-11
AR106013A1 (es) 2017-12-06
SI3313845T1 (sl) 2021-01-29
WO2017004025A1 (en) 2017-01-05
JP2024067036A (ja) 2024-05-16
HRP20201790T1 (hr) 2021-02-05
AU2022202208A1 (en) 2022-04-21
MD3313845T2 (ro) 2021-02-28
CN113769108A (zh) 2021-12-10
CN107708810B (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
CN113769108B (zh) 半胱氨酸工程化抗体的结合物
KR102638901B1 (ko) 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
EP3189056B1 (en) Cytotoxic benzodiazepine derivatives
RU2834224C1 (ru) Конъюгаты сконструированных антител с цистеиновыми заменами
HK40044772A (en) Conjugates of cysteine engineered antibodies
HK40046012A (en) Cytotoxic benzodiazepine derivatives
HK1254782B (en) Conjugates of cysteine engineered antibodies
HK1236943B (en) Cytotoxic benzodiazepine derivatives
HK1236943A1 (en) Cytotoxic benzodiazepine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant